Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
Priced IPO
Solaredge Technologies, Inc. (SEDG)
The Marygold Companies (MGLD)
Blue Water Vaccines (BWV)
Meihua International Medical Technologies (MHUA)
Smart for Life (SMFL)
Vivakor (VIVK)
TC BioPharm Holdings (TCBP)
Direct Digital Holdings, Llc (DRCT)
Modiv (MDV)
Sky Technologies (SKYX)
Modular Medical (MODD)
HeartCore Enterprises (HTCR)
Arcellx, Inc. (ACLX)
Silver Spike Investment Corp. (SSIC)
Maris-Tech Ltd. (MTEK)
Yoshitsu Co., Ltd. (TKLF)
Tpg Inc. (TPG)
Hillstream BioPharma (HILS)
Hour Loop (HOUR)
Vigil Neuroscience, Inc. (VIGL)
More companies

Atai Life Sciences B.v. (ATAI)

Sector - Healthcare

Price chart

N/A
Return from IPO

Company News

IPO Profile

About company

Company Logo
They are a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. They founded atai Life Sciences in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, as well as the emergence of therapies that previously may have been overlooked or underused, including psychedelic compounds and digital therapeutics. They have built a pipeline of 10 development programs and six enabling technologies, each led by focused teams with deep expertise in their respective fields and supported by their internal development and operational infrastructure. They believe that several of their therapeutic programs’ target indications have potential market opportunities of at least $1 billion in annual sales, if approved. One of their atai companies, Recognify Life Sciences, has initiated a Phase 2a trial in the United States. They expect to initiate a Phase 2 trial for another program in 2021 and an additional three Phase 2 trials for other programs in 2022. They also expect to initiate Phase 1 trials for three of their programs in 2021 and an additional four in 2022.
Industry
Pharmaceutical Preparations
CEO CFO
Florian Brand Greg Weaver
Employees Founded
35 2018

Contacts

Address: C/o Mindspace Krausenstraße 9-10 10117 Berlin, Germany

Telephone: +49 89 2153 9035

Web page: http://www.atai.life

IPO information

First Trade Date 6/18/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 14.3
Shares Revised (MM) 15
Expected offer amount (MM) $200.2
Realized offer amount(MM) $225

Financial Data (last reporting year)

Market Cap (MM) $2126.04
Revenues (MM) $19.88
Net Income (Loss) (MM) $-153.54

Voting

What do you think will happen with the ATAI share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Credit Suisse

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
Credit Suisse/ Citigroup/ Cowen/ Berenberg
CO-Managers
Cantor/ RBC/ Canaccord Genuity

Sector: Healthcare

Tweets about $ATAI

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats